Navigation Links
Insmed to Host 2011 Third Quarter Earnings Conference Call
Date:10/25/2011

MONMOUTH JUNCTION, N.J., Oct. 25, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, November 8th, 2011, at 8:30 AM ET, to discuss its financial results for the third quarter of 2011.  Insmed intends to issue its quarterly financial results press release before the market opens on November 8th.

To participate in the live conference call, please dial 866-362-4831 (U.S. callers) or 617-597-5347 (international), and provide passcode 11382552.  A live webcast of the call will also be available at http://www.media-server.com/m/p/8yh5aes3.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on November 8th, at 1-888-286-8010 (U.S. callers) or +1-617-801-6888 (international), using passcode 25135317.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial positions, results of operations, the results of clinical trials and clinical data described herein, the development of our products, and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may be affected by such factors as the receipt and timing of FDA and other regulatory approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, our future clinical trials may not support the data described in this release, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, we may experience delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2010.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie – FTI Consulting

212-850-5683

brian.ritchie@fticonsulting.com

Media Contact:

Irma Gomez-Dib – FTI Consulting

212-850-5761

irma.gomez-dib@fticonsulting.com

 


'/>"/>
SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
2. Insmed to Present at BioPharm Asia 2008 Conference
3. Insmed to Present at Biosimilars 2008 Conference
4. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
5. Insmed to Seek Shareholder Approval for Reverse Split
6. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
7. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
8. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
9. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
10. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , ... February 28, 2017 , ... ... most advanced manufacturing technology for use in filling injectable drug products into vials, ... Vanrx Pharmasystems SA25 robotic work-cell . CEO of Singota Solutions Alisa Wright expressed ...
(Date:2/28/2017)... Feb. 28, 2017  Phosphorus, a computational genomics ... formation of the Phosphorus Scientific Advisory Board, an ... to advise the company on the development of ... initiatives. Please visit http://phosphorus.com/about-us/ to learn ... "We,ve gathered some of the top leaders ...
(Date:2/28/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... company, today announced that its Lab Testing Division(LTD),s ... once again passed US FDA,s bioequivalence (BE) inspection ... from FDA thoroughly audited WuXi,s quality system during ... operation infrastructure, equipment, sample storage, archival system, quality ...
(Date:2/28/2017)... CA (PRWEB) , ... February 28, 2017 , ... ACEA ... the treatment of chronic diseases, has announced Dr. Roger (Feng) Luo as the new ... development experience with a number of multinational drug companies, Dr. Luo will now team ...
Breaking Biology Technology:
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
Breaking Biology News(10 mins):